Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2 USD | +2.04% | -1.96% | +29.03% |
Financials (USD)
Sales 2024 * | 110M | Sales 2025 * | 72.48M | Capitalization | 135M |
---|---|---|---|---|---|
Net income 2024 * | -12M | Net income 2025 * | -52M | EV / Sales 2024 * | 1.24 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.87 x |
P/E ratio 2024 * |
-13.3
x | P/E ratio 2025 * |
-4.03
x | Employees | 121 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.97% |
Latest transcript on CytomX Therapeutics, Inc.
1 day | +2.04% | ||
1 week | -52.27% | ||
Current month | +22.70% | ||
1 month | +1.52% | ||
3 months | +33.33% | ||
6 months | +55.04% | ||
Current year | +29.03% |
Managers | Title | Age | Since |
---|---|---|---|
Sean McCarthy
CEO | Chief Executive Officer | 57 | 10-11-30 |
Chris Ogden
DFI | Director of Finance/CFO | 40 | 21-08-01 |
Marcia Belvin
CTO | Chief Tech/Sci/R&D Officer | 57 | 17-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Meyers
BRD | Director/Board Member | 59 | 18-12-19 |
Elaine Jones
BRD | Director/Board Member | 69 | 14-11-30 |
Sean McCarthy
CEO | Chief Executive Officer | 57 | 10-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 2 | +2.04% | 3,288,698 |
24-05-15 | 1.96 | +1.03% | 3,922,236 |
24-05-14 | 1.94 | +2.65% | 4,577,284 |
24-05-13 | 1.89 | -4.55% | 6,114,521 |
24-05-10 | 1.98 | -2.94% | 12,154,821 |
Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+29.03% | 133M | |
+8.29% | 113B | |
+10.21% | 106B | |
+0.41% | 22.27B | |
-11.90% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-5.17% | 17.24B | |
+7.70% | 14.29B | |
+37.65% | 12.52B |
- Stock Market
- Equities
- CTMX Stock